Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14451934 | 0.77 | ATM (0.38) | TDP1POLB | |
| SCHEMBL4051027 | 0.71 | MEN1 (0.35) | BRD4BRD9SIRT3TDP1SMN1; SMN2 | |
| SCHEMBL24890410 | 0.65 | KMT2A (0.33) | BRD4TDP1 | |
| SCHEMBL12493617 | 0.64 | GPR35 (0.41) | TDP1 | |
| SCHEMBL18060822 | 0.64 | — | — | |
| SCHEMBL28782535 | 0.64 | GPR35 (0.37) | TDP1SMN1; SMN2POLB | |
| SCHEMBL1662848 | 0.64 | — | — | |
| SCHEMBL22528158 | 0.62 | BRD4 (0.35) | BRD4BRD9SMN1; SMN2PARP1POLB | |
| SCHEMBL1665468 | 0.62 | BRD4 (0.38) | BRD4BRD9SIRT3TDP1SMN1; SMN2 | |
| SCHEMBL4051746 | 0.62 | PARP1 (0.36) | BRD4BRD9PARP1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116371417-B | Catalyst for synthesizing 3, 4-dimethyl pyrrole and preparation method and application thereof | 济南悟通生物科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116478080-B | Synthesis method of 3, 4-dimethylpyrrole | 济南悟通生物科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116478080-A | Synthesis method of 3, 4-dimethylpyrrole | 济南悟通生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116371417-A | Catalyst for synthesizing 3, 4-dimethyl pyrrole and preparation method and application thereof | 济南悟通生物科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | BRD4 1440/4885BRD9 2232/4885SIRT3 611/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | BRD4 1440/4885BRD9 2232/4885SIRT3 611/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | BRD4 1440/4885BRD9 2232/4885SIRT3 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.